The use of innovative payment mechanisms for gene therapies in Europe and the USA
| Autor: | Panos Kefalas, Jesper Jørgensen |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Embryology
Public economics 030503 health policy & services media_common.quotation_subject Biomedical Engineering Market access Reimbursement Mechanism Payment Europe Reimbursement Mechanisms 03 medical and health sciences 0302 clinical medicine Incentive Willingness to pay Product value 030212 general & internal medicine Business 0305 other medical science Delivery of Health Care Reimbursement media_common Healthcare system |
| Zdroj: | Regenerative medicine. 16(4) |
| ISSN: | 1746-076X |
| Popis: | Innovative reimbursement mechanisms have long been considered potential solutions to the data uncertainty associated with one-off, high-value gene therapies that have long-term therapeutic potential, combined with limited supporting evidence at launch. The launches of increasing numbers of such gene therapies in Europe and the USA in the past 5 years provide valuable exemplars of how innovative reimbursement mechanisms are used by healthcare system decision makers in practice. This review details the use of such reimbursement schemes for recently launched gene therapies in key European countries and the USA, and shows that they are more widespread in Europe than in the USA. Although innovative payment schemes are increasingly used across countries, differences in healthcare system structures (e.g., single- vs multi-payer systems) and willingness to pay mean that decision makers in different countries have different incentives to manage uncertainties around long-term, real-world product value. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|